Guardant Health rises after Q4 revenue surpasses estimate

Guardant Health

12/01/2026 12:15

** Medical diagnostics co Guardant Health GH.O shares rise 2% to $112.35 premarket

** Co reports preliminary Q4 revenue of $280 mln vs analysts' average estimate of $268 mln, according to data compiled by LSEG

** Attributes performance to year-on-year surge in oncology testing volumes by 38%

** Co also attributes performance to wider adoption of its Smart Liquid Biopsy platform

** Volumes for co's blood-based cancer screening test, Shield, increase nearly six times

** GH stock more than tripled over past year

(Reporting by Utkarsh Tushar Hathi)

((utkarshtushar.hathi@thomsonreuters.com))